Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Randomized Trial Examining the Growth and Safety Effects of Treatment With Recombinant Growth Hormone on Infants Aged 1 to 2 Years With Growth Retardation Secondary to Chronic Renal Insufficiency

NCT00184769 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00184769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00184769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Randomized Trial Examining the Growth and Safety Effects of Treatment With Recombinant Growth Hormone on Infants Aged 1 to 2 Years With Growth Retardation Secondary to Chronic Renal Insufficiency
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
January 29, 1998
Completion date
December 21, 2005
Enrollment
16 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, chronic renal insufficiency